Aardvark Therapeutics
(NASDAQ) AARD
Aardvark Therapeutics Financials at a Glance
Market Cap
$166.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$69.87M
EPS (TTM)
-$3.21
P/E Ratio
-2.37
Dividend
$0.00
Beta (Volatility)
1.71 (High)
Dividend
$0.00
Beta (Volatility)
1.71 (High)
Price
$7.41
Volume
25,885
Open
$5.03
Price
$7.41
Volume
25,885
Open
$5.03
Previous Close
$7.60
Daily Range
$5.03 - $7.92
52-Week Range
$3.35 - $17.94
Estimated Earnings Date
Aug 12, 2026
Dividend
$0.00
Beta (Volatility)
1.71 (High)
Price
$7.41
Volume
25,885
Open
$5.03
Previous Close
$7.60
Daily Range
$5.03 - $7.92
52-Week Range
$3.35 - $17.94
Estimated Earnings Date
Aug 12, 2026
AARD News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Aardvark Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
40
CEO
Tien Li Lee, MD
Website
www.aardvarktherapeutics.comHeadquarters
San Diego, CA 92122, US
AARD Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-61.71%
Return on Capital
-58.58%
Return on Assets
-70.87%
Earnings Yield
-42.19%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$166.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
21.88M
Volume
25.89K
Avg. Volume
261.77K
Financials (TTM)
Gross Profit
$0.00
Operating Income
-$74.72M
EBITDA
-$69.83M
Operating Cash Flow
-$61.65M
Capital Expenditure
-$95.00K
Free Cash Flow
-$61.75M
Cash & ST Invst.
$91.20M
Total Debt
$336.00K
Aardvark Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
$166.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$4.16M
N/A
Employees
40
N/A
Net Income
-$21.59M
-131.9%
EBITDA
-$21.58M
-131.9%
Quarterly Fundamentals
Total Cash
$91.20M
-39.7%
Total Debt
$336.00K
-53.7%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$336.00K
-13.8%
Return on Assets
-70.87%
N/A
Return on Invested Capital
-85.90%
N/A
Free Cash Flow
-$18.87M
-65.7%
Operating Cash Flow
-$18.87M
-65.7%